【摘要】 目的 :探讨新辅助化疗在治疗中晚期鼻咽癌 (nasopharyngealcarcinoma ,NPC)中的应用价值。方法 :经病理检查确诊的 80例中晚期 (Ⅱ～Ⅳ期 )初治NPC患者 ,于放疗前随机分成两组 ,即新辅助化疗 +放射治疗组 (化放组 )和单纯放疗组(单放组 )各 4 0例 ,观察新辅助化疗对肿瘤患者的缓解率和毒副反应 ,对比放射治疗后两组的疗效。结果 :化放组的全身性毒副反应发生率、复发率及转移率均较低 ,而肿瘤控制率及生存率明显高于单放组 ;化疗组与单放组的 5年生存率分别为 6 5 %和 4 2 5 % ,两组间相比较均有显著性差异 (P值均 <0 0 5 )。结论 :对中晚期NPC宜先进行新辅助化疗 ,再行放射治疗 ,可以提高疗效更多还原

【Abstract】 Objective:TO evaluate the efficacy of neoadjuvant chemotherapy in the treatment of medium or terminal stage of nasopharyngeal carcinoma.Methods:80 cases of histologically proven nasopharyngeal carcinoma (Stage Ⅱ to Ⅳ) were divided averagely two groups by random, one group of patients were treated by radiotherapy alone and the other group were treated by neoadjuvant chemotherapy before radiotherapy (Combined group). The toxicity of chemotherapy and the effect of the two therapeutic schemes were observed.Results:The chemotherapy toxicity reaction was comparatively mild, there were lower relapse and metastasis rates in the patients who were treated by neoadjuvant chemotherapy before radiotherapy and the 5 years survival rate in combined therapeutic group and radiotherapy alone group was 65% and 42.5% respectively (P<0.05). Conclusion:Neoadjuvant chemotherapy used before radiotherapy is recommended by us in the treatment of medium or terminal stage of nasopharyngeal carcinoma.更多还原